Business Context and Reporting Period
Revolution Medicines, Inc. (RVMD) is a clinical-stage precision oncology company developing novel targeted therapies for RAS-addicted cancers. This summary covers the quarterly period ended September 30, 2025 (Q3 2025), and the nine months ended September 30, 2025 (YTD 2025). The company has no products approved for commercial sale and has incurred net operating losses since inception.
Key Financial Metrics
| Metric | Q3 2025 | Q3 2024 | YTD 2025 | YTD 2024 |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| Net Loss | $(305.2) million | $(156.3) million | $(766.4) million | $(405.5) million |
| Net Loss Per Share | $(1.61) | $(0.94) | $(4.06) | $(2.45) |
| Operating Expenses | $315.3 million | $175.7 million | $820.7 million | $473.2 million |
| Research & Development (R&D) | $262.5 million | $151.8 million | $692.4 million | $404.1 million |
| General & Administrative (G&A) | $52.8 million | $24.0 million | $128.4 million | $69.1 million |
| Cash, Cash Equivalents & Marketable Securities | $1.93 billion | $2.30 billion (Dec 31, 2024) | $1.93 billion | $2.30 billion (Dec 31, 2024) |
| Net Cash Used in Operating Activities (YTD) | $(623.5) million | $(419.1) million | $(623.5) million | $(419.1) million |
| Accumulated Deficit | $(2.50) billion | $(1.74) billion (Dec 31, 2024) | $(2.50) billion | $(1.74) billion (Dec 31, 2024) |
Material Changes vs. Prior Period
- Increased Operating Expenses: Total operating expenses increased by $139.6 million (79%) in Q3 2025 compared to Q3 2024. R&D expenses rose by $110.8 million, driven primarily by higher clinical trial costs for daraxonrasib ($41.0 million increase) and zoldonrasib ($17.7 million increase), as well as increased headcount and stock-based compensation. G&A expenses increased by $28.8 million due to commercial preparation and legal expenses.
- Financing Activities: In June 2025, the company entered into a Royalty Purchase Agreement with Royalty Pharma, receiving an upfront payment of $250.0 million. This is recorded as a liability related to the sale of future royalties, not revenue. Additionally, the company entered into a Term Loan Facility agreement for up to $750.0 million, though no amounts were drawn as of September 30, 2025.
- Interest Expense: Interest expense of $11.4 million was recorded in Q3 2025, primarily due to non-cash interest expense associated with the new Royalty Purchase Agreement. There was no interest expense in Q3 2024.
- Subsequent Event: In October 2025, the company sold approximately 3.5 million shares under its At-The-Market (ATM) program, generating gross proceeds of $185.7 million.
Guidance, Outlook, and Risks
- Liquidity: As of September 30, 2025, the company held $1.93 billion in cash, cash equivalents, and marketable securities. Management believes this is sufficient to fund planned operations for at least 12 months following the filing date.
- Clinical Pipeline Progress:
- Daraxonrasib (RMC-6236): Received Breakthrough Therapy Designation for metastatic pancreatic ductal adenocarcinoma (PDAC) in June 2025 and Orphan Drug Designation in October 2025. The Phase 3 RASolute 302 study is nearing enrollment completion with a readout expected in 2026.
- Elironrasib (RMC-6291): Received Breakthrough Therapy Designation for NSCLC in July 2025.
- Zoldonrasib (RMC-9805): Clinical data reported in May 2025 showed encouraging activity in NSCLC and PDAC.
- Risks and Contingencies:
- Regulatory Risk: The company has no approved products; success depends on clinical trial outcomes and regulatory approvals.
- Debt Covenants: The Royalty Purchase Agreement and Term Loan Facility contain covenants that may limit operating flexibility. Failure to comply could result in default.
- Legal Proceedings: The company has accrued $5.0 million for a potential settlement related to the Nemeth v. Casdin litigation regarding the EQRx merger.
- Capital Needs: The company expects to incur significant losses for the foreseeable future and will require substantial additional financing to advance its pipeline and prepare for commercialization.
Investor Verification Checklist
- Cash Runway: Verify the sufficiency of the $1.93 billion cash balance against the accelerating burn rate (YTD operating cash burn of $623.5 million).
- Royalty Agreement Terms: Review the specific triggers and royalty rates in the Royalty Pharma agreement, particularly the potential for additional tranches and the impact on future net sales.
- Clinical Trial Timelines: Monitor the enrollment status and expected readout dates for the Phase 3 RASolute 302 (daraxonrasib) and RASolve 301 (daraxonrasib) studies.
- ATM Program Utilization: Track the utilization of the $500 million ATM program, noting the $185.7 million raised in October 2025.
- Legal Accruals: Confirm the final settlement amount for the Nemeth v. Casdin litigation and any potential insurance recoveries.